key: cord-0778625-257c879e authors: Huang, Lianzhou; Chen, Yuanqiu; Xiao, Ji; Luo, Weisheng; Li, Feng; Wang, Yuan; Wang, Yiliang; Wang, Yifei title: Progress in the Research and Development of Anti-COVID-19 Drugs date: 2020-07-07 journal: Front Public Health DOI: 10.3389/fpubh.2020.00365 sha: 35ae1bf67ad4144a1252caa4dbf5061473202cf1 doc_id: 778625 cord_uid: 257c879e The outbreaks of COVID-19 due to SARS-CoV-2 has caused serious physical and psychological damage to global human health. COVID-19 spread rapidly around the world in a short time. Confronted with such a highly infectious respiratory disease, the research and development of anti-COVID-19 drugs became an urgent work due to the lack of specific drugs for the treatment of COVID-19. Nevertheless, several existing drugs are available to relieve the clinical symptoms of COVID-19. We reviewed information on selected anti-SARS-CoV-2 candidate therapeutic agents published until June 2, 2020. We also discussed the strategies of the development of anti-COVID-19 drugs in the future. Our review provides a novel insight into the future development of a safer, efficient, and toxic-less anti-COVID-19 drug. It was reported that a group of patients with pneumonia from an unknown cause were hospitalized at the end of 2019 (1). Most of them had respiratory symptoms, such as fever, cough, muscle soreness, headache, sore throat, chest pain, diarrhea, nausea, and vomiting, and among whom some even developed the complication of acute respiratory distress syndrome (ARDS) (2) . This pneumonia was caused by a novel coronavirus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a sister of SARS-CoV, as revealed by the subsequent result of gene sequencing (3) . The corresponding disease caused by SARS-CoV-2 was named 2019 coronavirus disease (COVID-19) (4) . Of note, SARS-CoV-2 exhibited a high level of person-to-person transmission (5) , which may be due to the strong affinity with its receptor Angiotensin-Converting Enzyme 2 (ACE2) (6) . The ongoing outbreak of COVID-19 had been announced as a global GRAPHICAL ABSTRACT | The life cycle of SARS-CoV-2 and the mechanism of actions of anti-COVID-19 drugs. The life cycle of SARS-CoV-2 in host cells includes: (1) Binding and penetration: SARS-CoV-2 binds to the ACE2 receptors on the cell membrane and entry into host cells through endocytosis. (2) Genome release: the genome of SARS-CoV-2 will be released following the process of membrane fusion. (3) Genome replication: the positive (+)-sense genomic RNA directs the synthesis of negative (−)-sense RNA, which can act as the template to synthesize the RNA chain of progeny virus. (4) Protein biosynthesis: negative (−)-sense RNA acts as a template, with mRNAs transcribed to direct the protein biosynthesis of SARS-CoV-2 via the translation process in the cytoplasm. (5) Assembly: the genomic RNA and virion proteins are reassembled to form a mature virion. (6) Release: the progeny viral particles are released through exocytosis. The levels of actions of corresponding drugs were also depicted. Remdesivir can inhibit the replication of the SARS-CoV-2 genome. The combination of lopinavir/ritonavir can block the maturation of protein. Chloroquine virtually interrupts the whole life cycle of SARS-CoV-2. The antibody within plasma can directly neutralize SARS-CoV-2. pandemic by the WHO on 11 March, 2020. According to the report from the Center for Systems Science and Engineering at Johns Hopkins University (last updated on 4/26/2020), the global cumulative number of confirmed cases of COVID-19 has reached 2,856,771, with 202,473 deaths (7) . Confronted with such a situation, the development of effective drugs for the treatment of COVID-19 has become a crucial and urgent work Abbreviations: ARDS, acute respiratory distress syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, 2019 coronavirus disease; ACE2, Angiotensin-Converting Enzyme 2; RdRp, RNA-dependent RNA polymerase; HIV-1, Human Immunodeficiency Virus 1; 3CL pro , 3-chymotrypsinlike cysteine protease; GLN, L-Glutamine; TLR7, toll-like receptor 7; TLR9, tolllike receptor 9; S, spike; M, membrane; N, nucleocapsid; E, envelope; ELISA, enzyme-linked immunosorbent assay; BLI, biolayer interferometry binding; ICU, intensive care unit; TLR4, toll-like receptor 4; AAV, adeno-associated virus; JAK, Janus kinase; RBD, receptor-binding domain. (8) . However, there is currently no specific drugs against SARS-CoV-2, despite some treatments that had been used in the clinical treatment of COVID-19 (9) . The mechanisms of actions of these drugs need to be elucidated and discussed. In this review, we summarized and discussed the currently available clinical treatment measures according to their mechanism of action and therapeutic effect ( Table 1) . The studies presented in this review were obtained from Google Scholar search engines and the PubMed database from searches up to June 2, 2020. Search terms include "COVID-19, " "SARS-CoV-2, " "anti-COVID-19 drugs, " "COVID-19 clinical trials, " and "development strategies of anti-COVID-19 drugs" in abstract, title, and keywords. The strategies of the future development of anti-COVID-19 drugs were also discussed. Our review would be beneficial for the development of more effective and toxic-less anti-COVID-19 drugs. The nucleoside analogs are important reagents for combating virus infection (10) . As one of the well-characterized adenosine analogs, remdesivir can restrain the proliferation of SARS-CoV, MERS-CoV, and Ebola virus in vitro (11) . Remdesivir can be integrated into the RNA chain of progeny virus as the substrate of the RNA-dependent RNA polymerase (RdRp), which inhibits the replication of viral genomes and thereby causes the mature termination of the virus (12) . It has also been verified that remdesivir can strongly interfere with the accomplishment of the SARS-CoV-2 life cycle in host cells (13) . The latest report indicated a clinical improvement of severe COVID-19 patients from multiple countries in 36 of 53 patients (68%) after treatment with remdesivir (14) . Due to such an excellent efficacy, remdesivir has entered into multiple clinical trials (15) . The results of a randomized, double-blind, placebo-controlled, multicentre trial suggested that whether intravenous remdesivir could decrease the time to clinical improvement in those treated earlier needs to be confirmed by further clinical studies. However, no statistically significant clinical benefits were observed in the remdesivir group compared with the placebo group in this clinical trial (16) . Indeed, a patient with COVID-19 successfully recovered after receiving remdesivir intravenously in the United States (17) , which further indicates that remdesivir would be rapidly applied as a clinical treatment for COVID-19 in the future. However, remdesivir has been found to cause side effects in the clinic, such as hypotension, increased hepatic enzymes, and renal impairment (14) . The mechanism responsible for the side effects of remdesivir is not clear. Further study is needed to address the mechanism of the side effects caused by remdesivir. Collectively, remdesivir is a relatively promising anti-SARS-COV-2 candidate therapeutic agent (18) . Lopinavir is an inhibitor of Human Immunodeficiency Virus 1 (HIV-1) protease (19) . The metabolism of lopinavir can be delayed by ritonavir to enhance the anti-HIV-1 effect of lopinavir; therefore, these two drugs are often used in combination (20) . The brand name of such a combined drug is Kaletra (21) , which displays a broad-spectrum antiviral activity, including on SARS-CoV-2 (22) . Mechanism studies suggested that the lopinavir/ritonavir combination may inactivate the 3chymotrypsin-like cysteine protease (3CL pro ) that cleaves protein precursors into a variety of active proteins required for the life cycle of SARS-CoV-2 (23). A non-comparative case series of 10 patients suggested that lopinavir may ameliorate the symptoms of COVID-19 (24) . After receiving lopinavir/ritonavir with arbidol combination therapy, the negative conversion rate of COVID-19 on the 7 and 14th days was significantly increased (25) . Indeed, the viral load of a COVID-19 patient who received lopinavir/ritonavir combination therapy was gradually decreased and even completely cleared within the next few days in Korea (26) . A retrospective analysis further supported that lopinavir is an effective drug for the treatment of COVID-19 (27) . However, no benefit was observed in COVID-19 patients who were receiving lopinavir/ritonavir combination therapy as revealed by a randomized, controlled, open-label trial (28) . Importantly, lopinavir/ritonavir combination (200 mg/50 mg/capsule, two capsules each time, twice per day for adults, the course of treatment should be <10 days) was recommended for the treatment of COVID-19 by the National Health Commission of China. However, the lopinavir/ritonavir combination can induce severe gastrointestinal effects for the treatment of COVID-19, the cause of which remains unknown (28) . Of note, the lopinavir/ritonavir combination can be used in combination with other drugs to alleviate adverse reactions, such as probiotics, soluble fiber, and L-Glutamine (GLN) (29) . Besides, the film-coated tablet formulation of lopinavir/ritonavir induces fewer gastrointestinal side effects than when used in tablet formulation (30) . Chloroquine is a cheap and safe drug that has been used in the clinic for more than 70 years (31) . Chloroquine is a firstline drug for the treatment of Plasmodium falciparum infection (32) . Importantly, chloroquine also exerts strong antiviral effects (33) . Mechanically, chloroquine can increase the pH of the intranuclear body, lysosome, and Golgi body, which jointly prevents virus penetration, genome replication, and assembly of mature viral particles (34) . Of note, it was confirmed that chloroquine can suppress the replication of SARS-CoV-2 in vitro with an EC 50 of 1.13 µM (13). Interim analysis of preliminary data from 23 ongoing clinical trials reported in a letter suggested that chloroquine phosphate is superior to the control treatment in inhibiting the exacerbation of COVID-19 pneumonia (35) . Hydroxychloroquine, a derivative of chloroquine, also can significantly inhibit the infection of SARS-CoV-2 on VeroE6 cells with weak toxicity (36) . An uncontrolled, non-comparative, observational study in a cohort of 80 inpatients reported clinical improvements and rapid fall of viral load after receiving hydroxychloroquine and azithromycin combination therapy (37) . However, the administration of hydroxychloroquine alone did not significantly increase the negative conversion rate in COVID-19 patients (38) . Indeed, chloroquine phosphate is recommended as an effective treatment by the National Health Commission of the People's Republic of China. There are more than 16 clinical trials aimed at determining the effectiveness of chloroquine in the treatment of COVID-19 (39) . If the result of the clinical trial supports the efficacy and safety of chloroquine against COVID-19, chloroquine will become one of the most available drugs for the treatment of COVID-19 (40) . Specifically, chloroquine and hydroxyquinoline could impair host immunity by inhibiting toll-like receptor 7 (TLR7) and toll-like receptor 9 (TLR9) signaling due to the increased pH (41) . In particular, a high dose of chloroquine and hydroxyquinoline can cause arrhythmias and even death by interfering with the polarization and depolarization of the heart (42). Indeed, it was recommended that <500 mg of chloroquine and hydroxyquinoline is used as a daily dose for adults and it is not advocated for long-term use; if long-term use is needed, the toxic-less hydroxychloroquine should be given priority (43) . The antibodies against SARS-CoV-2 produced by plasma cells can neutralize the virus to reduce its pathogenicity (44) . Scientists have been devoted to the development of antibodies against SARS-CoV-2 since the outbreak of COVID-19 (45) . SARS-CoV-2 contains four conserved structural proteins-the spike (S) protein, the membrane (M) protein, the nucleocapsid (N) protein, and the small envelope (E) protein (46)-in which the S protein shows excellent antigenicity (47) . Of note, the SARS-specific human monoclonal antibody CR3022 can bind to the S protein of SARS-CoV-2 as determined by enzyme-linked immunosorbent assay (ELISA) and biolayer interferometry binding (BLI) assay, whereas the clinical efficacy of CR3022 needs to be further verified (48) . Additionally, it has been reported that the antibodies within convalescent plasma can neutralize SARS-CoV-2 efficiently and rapidly (49) . As revealed by a clinical trial with a small sample size, the convalescent plasma may be a potential treatment for COVID-19 patients who were admitted to the intensive care unit (ICU) (50) . Similarly, another clinical trial also revealed the remarkable efficacy and feasibility of plasma therapy for the treatment of COVID-19 (51) . However, plasma therapy is limited by the shortage of its sources because an ideal therapeutic plasma should be compatible with the recipients (52) . Therefore, the collection, storage, and distribution of plasma would be crucial work for the development of plasma therapy (52) . Collectively, plasma therapy for the treatment of COVID-19 patients with systemic, severe, and critical conditions requires confirmation in larger studies. Glucocorticoid, also known as an adrenocortical hormone, is a steroid hormone secreted by the human adrenal gland (53) . As one of the most important physiological hormones, glucocorticoids can regulate the biosynthesis and metabolism of the host (54) . Significantly, glucocorticoid also shows a strong activity of anti-inflammation (55) . However, the longterm use of glucocorticoids also induces severe side effects, such as the increased risk of osteonecrosis, endocrine disorders, and heart failure (56) . During the outbreak of SARS in 2003, the clinical application of glucocorticoids was an inevitable choice for critically ill patients in China (57) . Glucocorticoids can inhibit cytokine storms and chemokines caused by SARS-CoV-2 to prevent acute lung injury and acute respiratory distress syndrome (58) . Although the clinical evidence does not support glucocorticoid treatment for SARS-CoV-2 infection (59), glucocorticoid can serve as adjuvant therapy for critical patients with COVID-19 (60) . The 6th edition of the Diagnosis and treatment plan of Corona Virus Disease 2019 recommended glucocorticoid [≤1-2 mg/(kg·day) of methylprednisolone] as an alternative therapy. Of note, glucocorticoid can attenuate the host immunity by inhibiting toll-like receptor 4 (TLR4) signaling and T cell activation, which may cause the secondary infection of other pathogens (61) . However, such side effects can be partly restored by the combination of thalidomide and glucocorticoid with a reduced dose of glucocorticoids (62) . Therefore, the usage and dose should be administered moderately according to the patient's condition when glucocorticoid is used to relieve inflammation of COVID-19 patients. Collectively, further randomized controlled trials are needed to determine the safety and feasibility of glucocorticoids in relieving inflammatory symptoms of COVID-19 patients (63) . In addition to the drugs mentioned above, some drugs with fewer reports showed the activity of anti-SARS-CoV-2. Specifically, cinanserin, another HIV-1 protease inhibitor, may be a potential drug against COVID-19 as indicated by molecular docking and antiviral activity assay (64) . It has been recently reported that baricitinib is also a potential option for COVID-19 patients via blocking the ACE2 receptor-mediated endocytosis, although its efficacy remains to be clinically tested (65) . Oseltamivir has been widely used for COVID-19 patients although the therapeutic effect on COVID-19 remains to be further explored (66) . Some nucleoside analogs, including favipiravir, penciclovir, and ribavirin, can significantly inhibit the proliferation of SARS-CoV-2 in vitro (13) . Among these, ribavirin can inhibit the replication of both DNA and RNA viruses (67) . The outbreak of COVID-19 raises a serious challenge to the global economy and human health; therefore, the development of an effective treatment for COVID-19 has become an urgent work (73) . Indeed, there has been no specific drug against coronavirus since the outbreak of SARS in 2003. The drugs currently used for the treatment of COVID-19 partly refer to those for the treatment of SARS and MERS (74) , which are still assessed in clinical trials. We should pay attention to the following aspects in the future development of anti-COVID-19 drugs. For one thing, the drugs capable of blocking any step of the virus life cycle can be designed as antiviral drugs. For example, camostat mesylate can significantly block the penetration of SARS-CoV-2 by inhibiting the activity of the serine protease TMPRSS2, which is a factor mediating the penetration of SARS-CoV-2 (75) . EK1, a pan-coronavirus fusion inhibitor, can interfere with the membrane fusion of SARS-CoV-2 with the host cell by targeting the S protein (76) . Similar to remdesivir, sofosbuvir, galidesivir, and tenofovir may also act as the substrate of RdRp to inhibit the SARS-CoV-2 genome replication as revealed by the molecular docking results (77) . The 3CL pro enzyme is responsible for cleaving polymeric protein precursors to produce many non-structural proteins that are required for the replication of SARS-CoV-2, which indicates that 3CL pro inhibitors, including celecoxib and alprazolam, can be used to combat COVID-19 (78) . Of note, based on targeting the ACE2 receptor, a previous study had discovered several potential anti-COVID-19 drugs by using computational methods, such as xanthones and hesperidin (79) . Indeed, the lack of specific drugs for combating SARS-CoV-2 was largely due to the incomprehensive recognition of the mechanism of SARS-CoV-2 infection in host cells (80) . Therefore, future work should focus on exploring the life cycle of SARS-CoV-2 in human cells and the detailed mechanism of the pathogenesis of SARS-CoV-2. For another, the alleviation of host inflammation is an essential and urgent work for COVID-19 patients with cytokine storm (81) . Of note, in addition to glucocorticoids mentioned above, there are other agents with an anti-inflammatory effect, such as tocilizumab and jakotinib, an interleukin-6receptor antagonist and Janus kinase (JAK) inhibitor, respectively (82) . Further, screening from FDA-approved drugs based on computational methods would be an ideal strategy to ensure the efficiency of anti-COVID-19 drugs development (83) . Indeed, the vaccine is crucial for the prevention and control of COVID-19. Scientists need to have a better understanding of the interaction between SARS-CoV-2 and the immune system. The S protein is an ideal antigen for the development of vaccines due to its high affinity with the ACE2 receptor (84) . In particular, the receptor-binding domain (RBD) element of the S protein may be applied to vaccine development (85) . LH participated in data collection, data analysis, drafting, and editing of the manuscript. YilW contributed to the critical review and revision of the manuscript. All authors reviewed, supported the final manuscript, and agreed to this publication. A novel coronavirus from patients with pneumonia in China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study A distinct name is needed for the new coronavirus Coronavirus disease 2019: coronaviruses and blood safety Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection An interactive web-based dashboard to track COVID-19 in real time World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19) Recent insights into 2019-nCoV: a brief but comprehensive review Nucleoside analogues for the treatment of coronavirus infections Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Compassionate use of remdesivir for patients with severe covid-19 Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial First case of 2019 novel coronavirus in the United States Treatment options for COVID-19: the reality and challenges Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations Lopinavir/ritonavir: a review of its use in the management of HIV infection Therapeutic management of patients with COVID-19: a systematic review Candidate drugs against SARS-CoV-2 and COVID-19 Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study Case of the index patient who caused tertiary transmission of Coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-a possible reference for coronavirus disease-19 treatment option A trial of lopinavirritonavir in adults hospitalized with severe covid-19 GLN) reduce nelfinavir (NFV)-or lopinavir/ritonavir (LPV/r)-related diarrhea Study of the gastrointestinal tolerance of a new tablet formulation of the lopinavir/ritonavir antiretroviral in HIV-infected patients The public health impact of chloroquine resistance in Africa Novel antimalarial chloroquine-and primaquine-quinoxaline 1, 4-di-N-oxide hybrids: design, synthesis Effects of chloroquine on viral infections: an old drug against today's diseases Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a 6-days follow up: a pilot observational study Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial Of chloroquine and COVID-19 Chloroquine for the 2019 novel coronavirus SARS-CoV-2 Hydroxychloroquine in systemic lupus erythematosus (SLE) Cardiotoxicity of antimalarial drugs Caution and clarity required in the use of chloroquine for COVID-19 Jr Principles of broad and potent antiviral human antibodies: insights for vaccine design Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody Convalescent plasma as a potential therapy for COVID-19 Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Convalescent plasma to treat COVID-19: possibilities and challenges Glucocorticoid sexual dimorphism in metabolism: dissecting the role of sex hormones Chronopharmacology of glucocorticoids The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights Long-term side effects of glucocorticoids Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis. Osteoporosis Int Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia Fatal aspergillosis in a patient with SARS who was treated with corticosteroids Repurposing antiviral protease inhibitors using extracellular vesicles for potential therapy of COVID-19 On the use of corticosteroids for 2019-nCoV pneumonia Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Drug treatment options for the 2019-new coronavirus (2019-nCoV) Broad-spectrum antiviral activity of virazole: 1-f8-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide Arbidol as a broad-spectrum antiviral: an update Antiviral activities of type I interferons to SARS-CoV-2 infection Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2) Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) Anti COVID-19 drugs: need for more clinical evidence and global action The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pancoronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods Potential treatments for COVID-19; a narrative literature review COVID-19: combining antiviral and anti-inflammatory treatments The use of antiinflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China Current trends in virtual high throughput screening using ligand-based and structure-based methods Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2020 Huang, Chen, Xiao, Luo, Li, Wang, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.